36288-93-4

Upstream product

• 61141-14-8 anionic phenyl salicylate 
• 107-15-3 ethylenediamine 
• 1204318-12-6 benzyl 2-(2-hydroxybenzamido)ethylcarbamate 
• 119-36-8 methyl salicylate 
• 6345-72-8 N,N'-bis(2-hydroxybenzoyl)ethylenediamine 
• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 118-55-8 phenyl Salicylate 
• 69-72-7 salicylic acid 

Downstream Products

• 1202748-58-0 (E)-N-(2-(3,5-dibromo-2-hydroxybenzylideneamino)ethyl)-2-hydroxybenzamide 
• 1202748-56-8 (E)-2-hydroxy-N-(2-(2-hydroxy-5-iodobenzylideneamino)ethyl)benzamide 
• 1202748-52-4 (E)-2-hydroxy-N-(2-(2-hydroxybenzylideneamino)ethyl)benzamide 
• 1202748-54-6 (E)-N-(2-(5-chloro-2-hydroxybenzylideneamino)ethyl)-2-hydroxybenzamide 
• 1202748-60-4 (E)-2-hydroxy-N-(2-((2-hydroxynaphthalen-1-yl)methyleneamino)ethyl)benzamide 
• 1204317-86-1 N-(2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido] ethyl)-2-hydroxybenzamide 
• 1350454-81-7 N-(2-(4-(6-(3-methoxyphenyl)imidazo[2,1-b]thiazol-5-yl)pyrimidin-2-ylamino)ethyl)-2-hydroxybenzamide 
• 1644598-99-1 N-{2-[(2-hydroxybenzoyl)amino]ethyl}-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide 
• 219721-34-3 N-(2-hydroxybenzylidene)-N'-(2-hydroxybenzoyl)ethylenediamine 
• 1261242-29-8 C₂₄H₁₉FN₆O₂S 
• 850034-01-4 N-[2-(2,2-dimethoxy-ethylamino)-ethyl]-2-hydroxy-benzamide 

Relevant academic research and scientific papers

Substituent-tuned structure and luminescence sensitizing towards Al3+ based on phenoxy bridged dinuclear EuIII complexes

To develop a LnIII complex-supported chemsensor, two new phenoxy bridged dinuclear EuIII complexes, [Eu2(H2L)3(NO3)3]·3CH3CN (EuL) and [Eu2(H2L′)2(NO3)4]·3CH3CN (EuL′), constructed by two new structurally related salicylamide salen-like ligands, 1-(2-hydroxy-benzamido)-2-(2-hydroxy-5-nitro-benzylideneamino)-ethane (H3L) and 1-(2-hydroxy-benzamido)-2-(2-hydroxy-4-diethylamino-benzylideneamino)-ethane (H3L′), have been synthesized and structural analysis shows that the different substitution groups on 2-(iminomethyl)phenol moiety have significant effects on their structures. Upon excitation of the ligand-centered absorption band at 375 nm, emissions both originating from ligands and EuIII ions were observed in the two EuIII compounds with the EuIII-centered emission intensity more than three times higher than that of ligand-centered emission. The capability of EuL and EuL′ for selective detection Al3+ ions were evaluated and the results indicate EuL exhibits a turn-on luminescent enhancement as high as 5.7 fold with Kd = 1.53 × 10-4 in CH3CN, but comparable compound EuL′ could not detect Al3+ among various cations. The considerably 'turn-on' luminescence response of EuL concomitantly led to the apparent color change from reddish to brilliant red, which could also be identified by naked eyes easily under UV lamp. This luminescence enhanced response can be explained in terms of the decrease of non-radiative transitions in EuL in addition to excited-state intra-molecular proton transfer (ESIPT) and photo-induced electron transfer suppression upon Al3+ coordination which is also rationalized by a theoretical calculation.

Metal Complex Lipids for Fluid–Fluid Phase Separation in Coassembled Phospholipid Membranes

We demonstrate a fluid–fluid phase separation in 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) membranes using a metal complex lipid of type [Mn(L1)] (1; HL1=1-(2-hydroxybenzamide)-2-(2-hydroxy-3-formyl-5-hexadecyloxybenzylideneamino)ethane). Small a

Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies

A series of imidazothiazole derivatives possessing potential activity against melanoma cells were investigated for molecular mechanism of action. The target compounds were tested against V600E-B-RAF and RAF1 kinases. Compound 1zb is the most potent agains

COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY

The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti- inflammatory compound.

Synthesis, structure activity relationship and in vitro anti-influenza virus activity of novel polyphenol-pentacyclic triterpene conjugates

It is urgently necessary to develop more effective anti-influenza agents due to the continuous emergence of drug-resistant strains of influenza virus. Our earlier studies have identified that certain pentacyclic triterpene derivatives are effective inhibitors of influenza virus infection. In the present study, a series of C-28 modified pentacyclic triterpene derivatives via conjugation with a series of polyphenols were synthesized, and their antiviral activities against influenza A/WSN/33 (H1N1) virus in MDCK (Madin-Darby canine kidney) cells were evaluated. Four compounds 23m, 23o, 23q and 23s displayed robust anti-influenza potency with averaged IC50 values at the low-micromole level, surpassing the potency of oseltamivir. In addition, the in vitro cytotoxic activity of the four conjugates against MDCK cells showed no toxicity at 100 μM. Further mechanism studies of compound 23s, one of the best representative conjugates with IC50 value of 5.80 μM and a selective index (SI) value of over 17.2, by hemagglutination inhibition (HI), surface plasmon resonance and molecular modeling indicated that this conjugate bound tightly to the viral envelope hemagglutinin (KD = 15.6 μM), thus blocking the invasion of influenza viruses into host cells.

Pyrazines, its composition and use thereof

The invention relates to a pyrazine compound and application thereof as a medicine, in particular to application thereof to preparation of medicines for preventing and treating various influenza viruses. Particularly, the invention relates to a compound shown in the general formula I and a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, pharmaceutically acceptable salt or a prodrug thereof, and all variables are defined in the description. The invention also relates to a compound shown in the general formula I and application of a stereoisomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, pharmaceutically acceptable salt or a prodrug as medicines, particular to application thereof as medicines for preventing and treating influenza viruses.

Proximity effect on the general base catalysed hydrolysis of amide linkage: The role of cationic surfactant, CTABr

The bis phenoxide forms of (1,2) bis(2-hydroxybenzamido) ethane(I) , (1,5) bis(2-hydroxybenzamido) 3-azapentane(II) , (1,3) bis(2-hydroxybenzamido) propane(III) , and (1,8) bis(2-hydroxybenzamido) 3,6- diazaoctane(IV) undergo facile hydrolysis of one of the amide groups (0.02 ≤ [OH?]T (mol dm? 3) ≤ 0.5, 10% MeOH (v/v) + H2O medium) without exhibiting [OH?] dependence. The reactivity trend follows I ～ II >> III ～ IV with low activation enthalpy {25.7±2.8 ≤ δH≠ (kJ mol?1) ≤ 64.8±7.0}. The high negative and comparable values of activation entropy{?234 ±8 ≤ δS≠ (J K?1 mol? 1) ≤ ?127 ± 20} are consistent with closely similar, and ordered transition states which can be assembled by favourably oriented phenoxide groups. The solvent kinetic isotope effect for I, κ H2O/κ D2O+H2O ～ 1 (20 and 50 volume% D2O) , indicates that proton transfer is not involved as a part of the rate controlling process. The observed slowing down of the rate of this reaction for I in the micellar pseudo phase of CTABr also supports the proposed mechanism. Under premicellar conditions, however, rate acceleration is observed, a consequence believed to be associated with the capping effect of the hydrophobic tail of the surfactant cation forming the reactive ion-pair, CTA+, (I-2H) 2? exclusively in the aqueous pseudo phase. Indian Academy of Sciences.

New imidazo[2,1-b]thiazole derivatives: Synthesis, in vitro anticancer evaluation, and in silico studies

A series of 18 new imidazo[2,1-b]thiazole derivatives was synthesized. Their in vitro antiproliferative activities against A375P human melanoma cell line and NCI-60 cell line panel were tested. Compounds 15, 16, 18, 22, 26-28, and 31 showed superior poten

FATTY ACID ACETYLATED SALICYLATES AND THEIR USES

The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.

Synthesis of new 6-(4-Fluorophenyl)-5-(2-substituted pyrimidin-4-yl) imidazo[2,1-b] thiazole derivatives and their antiproliferative activity against melanoma cell line

Synthesis of a new series of pyrimidinyl-imidazo[2,1-b]thiazole derivatives is described. Their antiproliferative activity against A375 human melanoma cell line was tested and the effect of substituents on the pyrimidinyl ring side chain was investigated.